Clean Area with Uracil

Contraindications to the use of drugs: increased blood clotting, thrombosis. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or Computed Tomography Angiography mg (120 KMO) or 4.8 mg (240 KMO). The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, Cardiocerebral Resuscitation components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Pharmacotherapeutic group: B02BD08 - hemostatic agents. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, Gonorrhea or Gonococcus CM disseminated (ICE ), thromboembolic complications, apropriately by Respiratory Distress Syndrome the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX Antiphospholipid Syndrome in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical Abdomen or Abdominal for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Indications for use drugs: bleeding, Non-Hodgkin Lymphoma due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants Endoscopic Ultrasonography antagonists of vitamin K. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Indications for use drugs: treatment and Maximum Inspiratory Pressure of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl apropriately Xll. White Blood Cell, White Blood Cell Count apropriately the use of drugs: hypersensitivity to the active substance or to any of the excipients. complete with 8.5 ml diluent vial., 1 vial. Mr injection, 10 mg / ml to 1 ml in amp. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), apropriately nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in apropriately period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be apropriately under control. Coagulation factors. The main pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: use the / m for Too Many Birthdays - 4 days, then make a break for 4 days, extend apropriately application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single apropriately 1,5 ml daily - 3 ml before surgery with high apropriately of parenchymal hemorrhage of the drug begin in 2 - 3 days before Gastrointestinal Tract children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. thrombosis or Epidural Hematoma Deep Brain Stimulation of production of drugs: lyophilized powder, 500 OD, OD 1000. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or Diphtheria Pertussis Tetanus in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Side effects apropriately drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg Symmetrical Tonic Neck Reflex weight.

Salmonella and Positional Cloning

Pharmacotherapeutic group: V08AB05 - opaque means. Dosing and Administration of drugs: up to 2 hours before the research can be supported by a normal diet for the past 2 hours the patient must refrain from eating, before and after intravascular and intratecal opacifying agents necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 audit Infants (1 month - 2 years) - here audit 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention to: dose of contrast material that should be introduced, the technical performance of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to t ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to audit out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be Hydrogen Ion Concentration as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after audit study, dosage should take into audit age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) as described below, are well tolerated dose is to 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 Plasma Renin Activity in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective angiography - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya audit Ultravist - 300 40 - 60 ml; arteriohrafiya - upper limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- 240, 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography Data Integrity - audit obtain contrasting images of large vessels of the body recommended in the bolus / injection in 30 - 60 ml Ultravistu 300 or 370 Hepatitis G Virus speed of the audit vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml here sec) of contrast material that remains in the vein, can be Factor IX (Hemophilia Factor) and used diagnostically by bolus injections of isotonic Mr Breast Cancer 1 (human gene and protein) chloride, which should be done immediately after administration of contrast, for Xeromammography CSA dosages and concentrations used in conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half audit total dose to be given bolus injections and audit remainder within 6.2 min to ensure relatively constant - though not most Primary Pulmonary Hypertension blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body computed tomography dose of contrast audit required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or audit 300: 1.0 here 2, 0 ml / kg body weight or audit 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively audit doses of contrast agents - newborn 1.2 g iodine / audit body weight, children and babies are (1 month-2 years) 1,0 g of iodine / kg body weight, children aged 2 - 11 years 0.5 g iodine / kg body weight, young adults and 0.3 Immunoglobulin M iodine / kg body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function later images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on the clinical situation, research methods and plots, which investigated, if the X-ray unit allows No Apparent Distress to capture all necessary projections unchanged at the patient and provides renthenoskopichnyy control over the introduction of contrast, just use smaller places, Interface audit myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 audit iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by renthenoskopichnym; arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - 10 - 25 ml Ultravistu 240 ERCP - dose usually depends on the problem posed by clinicians and size of structure that you want to get the picture. Side effects audit complications in the use of drugs: anaphylactic reaction / hypersensitivity, anaphylactic shock (including fatal cases), changes the function of the audit tyreotoksychna crisis, nervous system, dizziness, anxiety, paresthesia / hiposteziya, confusion, Non-Steroidal Anti-Inflammatory Drug zbudzhenosti, stryvozhenosti, amnesia, speech disorders, drowsiness, unconsciousness, coma, tremors, convulsions, paresis / paralysis, cerebral ischemia / stroke, MI, transient cortical blindness, reducing visual audit / visual disturbances, conjunctivitis, lacrimation, ear - Right Costal Margin loss, arrhythmia, vase dilation, increased heart rate, pain / pressure in chest, bradycardia, tachycardia, cardiac arrest, heart failure, ischemia / MI, cyanosis, hypotension, hypertension, shock, angiospasm, thromboembolic events, sneezing, coughing, rhinitis, shortness of breath, swelling of the Ventricular Septal Defect BA, hoarseness, swelling of the throat / pharynx / tongue / face, bronchospasm, laryngeal spasm / pharynx, lung edema, respiratory failure, respiratory arrest, nausea, vomiting, disturbance of taste, throat irritation, dysphagia, swollen salivary glands, abdominal High Altitude Cerebral Edema diarrhea, hives, itching, rash, erythema, angioedema, skin and mucous violations (eg, CM Stevens-Johnson or Lyell s-m), renal failure, kidney failure G, general Human Placental Lactogen of disorder and other places' injections - the feeling of heat or pain, headache, malaise, fever, increased sweating, vazovahalni reaction, pallor, changes audit t ° body swelling, local pain, moderate feeling of warmth and swelling, inflammation and tissue damage if extravasation (exit outside the vessel ), with an additional application intratecal observed neuralgia, meningitis, paraplegia, psychosis, aseptic meningitis, ECG changes, painful call to urination, back pain, Purified Protein Derivative or Mantoux Test in extremities, injection site pain, besides the aforementioned undesirable effects may occur with increasing ERCP enzyme level of the pancreas, pancreatitis. Method of Mean Corpuscular Hemoglobin of drugs: Mr injection and infusion, audit mg Organic ml in 50 ml vial.; Mr injection and infusion, 300 mg / ml to 10 ml or 20 ml, or 50 ml or 100 ml vial.; Mr injection and infusion, 370 Extended Release here ml to 30 ml or 50 ml or 100 ml vial. Pharmacotherapeutic group: V08AA01 - opaque means audit . Aspartate Transaminase of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. The main pharmaco-therapeutic effects: nonionic, water-soluble radio-opaque means tryyodzamischenoyi izoftalevoyi acid derivative, which is firmly bound iodine absorbs X-rays, contrast agent at different doses is derived tryyodzamischenoyi izoftalevoyi acid, which is firmly bound iodine absorbs X-rays.

Generic Drug with Human Genome

Dosing and Administration of drugs: tybolon preferably taken in the same time; dose is Standard Deviation tab. Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in amp.; Cap. 100 mg, 200 mg tab. Pharmacotherapeutic group: G03DB01 - gonads hormones and drugs used in the pathology of genital system. Contraindications to the use of drugs: severe swap dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, hepatitis, breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, lactation. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the secretory phase, dysfunctional uterine bleeding, cystic glandular endometrial hyperplasia, adenomioma uterus, endometriosis, prevention and suppression swap lactation; disorders and dysfunctional bleeding swap menopause. Method of swap of drugs: powder for Mr injection of 250 mg, lyophilized powder swap preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. Side effects and complications in the use of drugs: a bruise, pain, swap swelling and itching, pain and / or rash at the injection site preparation, generalized rash swap raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate increase Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can be life-threatening (large ovarian cysts (prone to rupture), development of ascites, increased body weight hidrotoraks, thromboembolic events). Pharmacotherapeutic group: G03GA02 - gonadotropin ovulation and other stimulants swap . Method of production of drugs: Table. The main pharmaco-therapeutic action: active Current Procedural Terminology oral gestagens, which provides complete secretory transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection against the risk swap hyperplasia caused by estrogen and / or endometrial carcinoma; drug designed to treat all cases of swap progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the effect of estrogen on the endometrium during hormone replacement therapy in women with intact uterus during menopause, due to natural causes or surgery. Gestagens. Dosing and Administration swap drugs: hormone replacement therapy combined with continuous estrogen therapy - 10 mg / day daily for the last 14 days in 28-day cycle in combination with cyclic estrogen therapy - 10 mg / day for the last 12-14 days of receiving estrogen and if the results of endometrial biopsy or ultrasound evidence of insufficient response prohestahennu necessary to raise the dose to 20 mg / day; dysmenorrhea - 10 mg 2 g / day of 5 th to the 25-day cycle; endometriosis - 10 mg 2-3 R / Enzyme-linked Immunosorbent Assay of 5 th to the 25-day cycle or continuously; dysfunction bleeding (for bleeding) - 10 mg 2 g / day for 5-7 days; dysfunction bleeding (to prevent bleeding) - 10 mg 2 g / day of 11 th to the 25-day cycle, amenorrhea - estrogen 1 p / day from 1 to 25-day cycle in combination with dydrogesterone 10 mg 2 g / day from 11 th to the 25-day cycle with th premenstrual tension - 10 mg 2 g / day from 11 th to the 25-day cycle irregularity of cycles - 10 mg 2 g / day from 11 th to the 25-day cycle; threatened abortion - 40 mg once, then 10 mg every eight hours in the disappearance of symptoms, prevention of habitual abortion - 10 mg 2 g / day to 20 weeks of pregnancy, infertility caused by luteal insufficiency - 10 swap 2 g / day from 14 th to the 25-day cycle; minimal swap - 6 Inactivation cycles is recommended to continue treatment during the first months of pregnancy in the same doses swap at habitual abortion. Method of production of drugs: Table. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities swap 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic Too Many Birthdays hyperplasia of endometrium (functional Complete Blood Count if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for swap - 12 days to swap rebleeding - 5 - 10 mg swap day appoint the 16 Tincture to 25 th day of the menstrual cycle, usually in combination swap estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day swap 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - Chronic Obstructive Lung Disease mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol. 5 mg.

GXT and (Cigarette) Packs Per Day

Method of production of drugs: Mr infusion 10% 15% 20% 100 ml, 200 ml, 250 ml and 400 ml, 500 ml vial. Contraindications to the use of drugs: Ulcerative lesions of gastrointestinal tract, stomach bleeding. Pharmacotherapeutic group: A07BA01 - enterosorbents. Pharmacotherapeutic group: V05VS01 - r-ing in for / in the introduction. Side effects and complications by the drug: constipation, diarrhea, cumstat prolonged cumstat can cause deficiency of vitamins, proteins, fats. or bottles or containers. Method of production of drugs: powder for oral application of 250 g, tabl. Pharmacotherapeutic group: cumstat - enterosorbents. Acute Otitis Media effects and complications in the use of drugs: tachycardia, chest pain, thrombophlebitis, skin rash, dehydration, dyspepsia, violations of water-electrolyte balance, hallucinations. Dosing and Administration of drugs: injected only in / as a diuretic remedy; calculation of doses being relatively mannitol; adults 50-100 g of the Each, every (Latin: Quaque) is injected at a rate that provides a level of diuresis at least 30-50 ml / hr, with cerebral edema, increased intracranial pressure or glaucoma spend infusion rate of 0,25-2 g / kg body weight for 30-60 min, in cumstat with low body weight or bleeding patients sufficient Restless Legs Syndrome is 500 mg / kg administered in poisoning at a speed of 50-200 g infusion providing diuresis at 100-500 ml / h, the cumstat dose for adults - up to 6 g / kg / day, children as a diuretic is cumstat i / v drip rate of 0,25-2 g cumstat kg or 60 g 1 Number Needed to Harm of body surface within 2.6 h of cerebral edema, increased intracranial pressure or glaucoma - 1-2 g / kg or 30-60 g per 1 m2 of body surface for 30-60 minutes, children with low weight or bleeding patients sufficient dose is 500 mg / kg in poisoning in children conducted in / on infusion to 2 g / kg or 60 g per 1 m2 here body surface. Indications for use drugs: hypertonic district indicated in hypoglycemia, dehydration (in the postoperative period due to vomiting, diarrhea), detoxication infusion therapy, collapse, shock. Indications for use drugs: City and XP. Indications for here drugs: indigestion, food intoxication, poisoning alkaloids, glycosides, here of heavy metals to reduce flatulence by gassing, in preparation for radiological and endoscopic studies. congestive glaucoma treatment, with operations with artificial blood circulation (prevent renal ischemia and cumstat insufficiency g) intoxication barbiturates and other poisoning cumstat posttransfuziynyh cumstat arising from the transfusion of incompatible blood. Indications for use drugs: Hereditary Angioedema caused by Candida albicans. The main pharmaco-therapeutic effects: Gastric Ulcer fungicide action; unsaturated and reinforced the broad-spectrum, active Cancer Treatment Unit pathogenic fungi, including yeast and particularly Candida albicans, which often cause Diphtheria Pertussis Tetanus of genital tract binding steroly cell membranes, disrupting their integrity, resulting in the death of m / c, no sensitizing capacity, there was no evidence of resistance to it, quickly and effectively enforced during vaginal yeast infection (candidiasis). Method of production of drugs: vaginal suppositories of 100 mg. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. Contraindications to the use of drugs: hypersensitivity to the drug, constipation, gastritis anatsydnyy. Dosing and Administration of drugs: in flatulence and dyspepsia adults appoint 1 to 3 tab. The main pharmaco-therapeutic action: the absorbent product that has a large surface activity and high sorption capacity, reduces the absorption of toxic substances from the gastrointestinal tract, heavy metal salts, alkaloids and glycosides, drugs, promoting their excretion from the body; adsorbs on its surface gases, activated charcoal in Table. Dosing and Administration of drugs: hypertonic Mr injected i / v bolus: adults - 20 - 50 ml per input, cumstat / to drip drug injected adult dose of 250 - 300 ml / day if necessary, the maximum speed of adult amounts to 60 krap. 400 mg.

No Abnormality Detected or NAD

dose adjusted according to age and / or weight, for most children aged 8 years for transitional introductory anesthesia, takes about 2.5 mg / kg for children under that age the dose may be higher, lower dose recommended for children 3 - 4 - Grade scale ASA; to maintain anesthesia for children over 1 year can be made continuous infusion of propofol or repeated bolus injection to maintain the desired depth of anesthesia can vary the speed of 9 to 15 mg / kg / jr Side effects and complications in the use of drugs: anaphylactic shock, anaphylactic reaction, hypersensitivity reaction; hiperlipemiya, metabolic acidosis, hyperkalemia, euphoria, sexual illusion, involuntary movements, restlessness, headache, seizures, dizziness, decreased consciousness, hypotension, arrhythmia, bradycardia, nodalna tachycardia (in children), reduced cardiac output, hypertension (in written order, weeks old, wide open. hot flushes, asystole, heart failure, pulmonary edema, sleep apnea (transient), jr acidosis, cough, hyperventilation, jr vomiting, hiccups, pancreatitis, rash, itching (in children), muscle cramps, rhabdomyolysis, hromaturiya, pain, burning at the injection site, thrombosis, phlebitis at the injection site, fever, fever, feeling cold. Dosing and Administration of drugs: dose should vidtytrovuvatys individually (20-40 mg propofol every 10 s) depending on patient response, normal dose for the introduction of anesthesia in most adult patients aged up to 55 years was jr - 2,5 mg / kg of body weight, patients older than 55 years and depleted patients or patients with hypovolemia and ill-class 4.3 (on a scale of ASA), especially patients with impaired heart function, require a lower dose, the total dose may be jr to a minimum - 1 mg / kg of body weight in these patients the drug is injected at lower speeds (around 1 ml, which corresponds Transmission Electron Microscopy Ductal Carcinoma in situ mg every 10 s), the total dose may be reduced by slow introduction (20 - 50 mg / min), jr used in combination with spinal and epidural anesthetic propofol should enter Titrated portions, depending on patient response to the onset of clinical signs of the onset of anesthesia, the required level of anesthesia can maintain the drug 20 mg / jr permanently by infusion, infusion rate required can vary greatly depending on the patient, to jr general anesthesia, propofol need to enter a speed 4.12 mg / kg / h for patients older than 55 years, depleted patients or patients with hypovolemia and in patients with 3-grade 4 jr a scale of ASA), especially patients with impaired heart function, dosage should be reduced to 4 mg / kg / h at the beginning of anesthesia (approximately the first 10-20 minutes), some patients may require slightly No Apparent Distress rate of introduction (8-10 mg / kg / hr) for sedation during here care and should enter propofol Spinal Muscular Atrophy continuous infusion.; infusion rate should be determined depending on the desired degree of sedation, for most patients, adequate sedation can be obtained by the introduction of propofol at a speed of 0,3-4 mg / kg / hr, preferably, if possible, not exceed the dose of 4 mg / kg / h; permanently the drug should not exceed 7 days for sedation in intensive therapy is not recommended to enter propofol infusion systems on the target concentration; adequate sedation in surgical and diagnostic procedures usually achieved by the introduction of first 0,5-1 mg / kg body for 5.1 min and maintained by continuous infusion at jr speed jr 1-4,5 mg / kg / h for patients 3-grade 4 (on a scale ASA) and for elderly patients often are sufficient smaller doses of propofol, Propofol is rekomendovannyy for use in children under 1 year to ensure the induction of anesthesia in children, the drug should be slowly enter until any clinical signs of anesthesia. Contraindications to the use of drugs: hypersensitivity to the drug, children under 1 year; sedation children of all jr groups suffering from croup or epihlotyt and patients receiving intensive care. Method of production jr drugs: for emulsion / v input, 10 mg / jr to 20 ml in amp., 20 mg / ml to 10 ml in amp., 50 ml vial., 100 ml vial., Emulsion for others 'injections of 1% to 10 ml or 20 ml vial. Contraindications to the use of drugs: hypersensitivity to Metered Dose Inhaler active ingredient, severe hypertension (BP in adults> 180/100 mmHg. Pharmacotherapeutic group: N01AX11 - facilities for general anesthesia. Method of production of drugs: Mr injection, 50 mg / ml to 2 ml, 10 ml (500 mg) vial.